Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother's vaccination in pregnancy in infants aged 2-11 months
Autor: | Merdrignac, Lore, Acosta, Lesly, Habington, Adele, Garcìa Cenoz, Manuel, Pandolfi, Elisabetta, Fabiánová, Kateřina, Jordan, Iolanda, O'Sullivan, Niam, Navasués, Ana, Tozzi, Alberto E., Zavadilová, Jana, Jané, Mireia, Cotter, Suzanne, Pitillas, Nerea I., Rizzo, Caterina, Křížová, Pavla, Hanslik, Thomas, Muñoz-Almagro, Carmen, Pastore, Lucia, Bacci, Sabrina, Moren, Alain, Valenciano, Marta, PERTINENT Group |
---|---|
Přispěvatelé: | Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Universitat Politècnica de Catalunya. ADBD - Anàlisi de Dades Complexes per a les Decisions Empresarials |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Vigilancia hospitalaria
Efectividad de la vacuna Ciències de la salut::Medicina [Àrees temàtiques de la UPC] Tos ferina -- Vacunes Mothers Pregnancy Humans Tos ferina Vaccine in pregnancy Vigilància hospitalària Pertussis Vaccine Vaccine effectiveness Vaccines PertussisVaccine effectiveness Whooping cough General Veterinary General Immunology and Microbiology Efectivitat de la vacuna Vacuna durant l'embaràs Vaccination Hospital surveillance Public Health Environmental and Occupational Health Hospitalization Vacuna en el embarazo Infectious Diseases Case-Control Studies Molecular Medicine Female |
Popis: | Background: PERTINENT is an active hospital-based surveillance system for pertussis in infants. In 2019, four of the six participating European countries recommended pertussis vaccination in pregnancy. Among infants aged 14 days before symptom onset. We excluded infants with unknown maternal or PV status or with mothers vaccinated ≤14 days before delivery. We calculated pooled VE as 100 * (1-odds ratio of vaccination) adjusted for study site, onset date in quarters and infants’ age group. Results: Of 829 infants presenting with pertussis-like symptoms, 336 (41%) were too young for PV. For the VE in pregnancy analysis, we included 75 cases and 201 controls. Vaccination in pregnancy was recorded for 9 cases (12%) and 92 controls (46%), adjusted VE was between 75% [95%CI: 35–91%] and 88% [95%CI: 57–96%]. Of 493 infants eligible for PV, we included 123 cases and 253 controls. Thirty-one cases and 98 controls recorded both PV with ≥ 1 dose and vaccination in pregnancy, adjusted VE was between 74% [95%CI: 33–90] and 95% [95%CI: 69–99]; 27 cases and 53 controls recorded PV only, adjusted VE was between 68% [95%CI: 27–86] and 94% [95%CI: 59–99]. Conclusion: Our findings suggest that vaccination in pregnancy reduces pertussis incidence in infants too young for PV. In infants aged 2–11 months, PV only and both PV and vaccination in pregnancy provide significant protection against severe pertussis. info:eu-repo/semantics/publishedVersion |
Databáze: | OpenAIRE |
Externí odkaz: |